Pralmorelin (GHRP-2)

Research dosages typically range from 100-300 mcg per administration, given subcutaneously 1-3 times daily. Common protocols: 100 mcg starting dose, titrated up by 50 mcg every 1-2 weeks to a target of 200-300 mcg daily. Anti-aging protocols often use 150 mcg before bed. Performance protocols may use 300 mcg 2-3 times daily. Best administered on an empty stomach. Rotate injection sites (abdomen, thigh, upper arm).

Binds with high affinity to the Growth Hormone Secretagogue Receptor 1a (GHS-R1a) in the anterior pituitary and hypothalamus, stimulating growth hormone release in a dose-dependent manner.

Suppresses somatostatin (growth hormone inhibiting hormone), amplifying the natural GH release signal and allowing for enhanced pulsatile GH secretion.

As a ghrelin receptor agonist, reliably induces sensations of hunger and increases food intake in humans through hypothalamic appetite centers.

Potently stimulates GH secretion from the pituitary, producing a substantial and reliable increase in plasma GH levels. Used clinically in Japan as a diagnostic agent for GH deficiency.

Through sustained GH elevation, may promote lean muscle mass accretion and fat reduction, particularly when combined with exercise and proper nutrition.

GH secretion is naturally highest during deep sleep; GHRP-2 administered before bed may enhance the natural nocturnal GH pulse and improve sleep quality.

Elevated GH levels support tissue repair, recovery from exercise, and wound healing through IGF-1 mediated anabolic pathways.

Reliably increases hunger and food intake via ghrelin receptor activation, potentially beneficial for individuals needing to increase caloric intake.

Diurnal and Daily Variations in Growth Hormone and Growth Hormone Stimulation Test in Male Cynomolgus Monkeys.

In vivo (Athens, Greece) · Taniguchi Y, Yoshikawa T, Yamada T

Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach.

Molecular diversity · Kanhed AM, Patel DV, Teli DM

Determination of the immunostimulatory drug-glucosoaminyl-muramyl-dipeptide-in human plasma using HPLC-MS/MS and its application to a pharmacokinetic ...

Biomedical chromatography : BMC · Moskaleva NE, Markin PA, Kuznetsov RM

Glycine-modified growth hormone secretagogues identified in seized doping material.

Drug testing and analysis · Gajda PM, Holm NB, Hoej LJ

Identification of a novel growth hormone releasing peptide (a glycine analogue of GHRP-2) in a seized injection vial.

Drug testing and analysis · Popławska M, Błażewicz A